CYTR News and Press, CytRx Corporation From 02/11/21

CytRx Corporation (OTCQB: CYTR) (“CytRx” or the “Company”), a specialized biopharmaceutical company focused on research and development for the oncology and neurodegenerative disease categories, today announced that it is now a part of the LD Micro Index ...

Biopharmaceutical company CytRx (CYTR) says that NantKwest and ImmunityBio's ongoing Phase 2 clinical trials of a novel combination immunotherapy – which include CytRx’s licensed drug aldoxorubicin – for locally advanced or metastatic pancreatic cancer have...

NantKwest and ImmunityBio’s QUILT 88 Trial Shows Novel Combination Immunotherapy, Which Includes Aldoxorubicin, Has More Than Doubled Historic Median Survival Rates in Patients CytRx Corporation (OTCQB:CYTR) (“CytRx” or the “Company”), ...

CytRx Corporation ([[CYTR]] -5.4%) announces that the FDA has extended the review period for its New Drug Application for arimoclomol to treat Niemann-Pick Disease Type C (“NPC”) by three months. The updated PDUFA target action date is June 17, 2021.Despite the delay, ...

CytRx Corporation (OTCQB: CYTR) (“CytRx” or the “Company”), a specialized biopharmaceutical company focused on research and development for the oncology and neurodegenerative disease categories, today provided an update on the U.S. Food and Drug Administratio...

Highlights That Potential Merger Can Help Accelerate Current and Future Clinical Programs Utilizing CytRx’s Licensed Drug Aldoxorubicin CytRx Corporation (OTCQB: CYTR) (“CytRx” or the “Company”), a specialized biopharmaceutical company ...

CytRx (CYTR) has announced that Orphazyme A/S (ORPH) announces the expansion of its U.S. presence and workforce ahead of potential Food and Drug Administration approval of arimoclomol for the treatment of Niemann-Pick disease Type C. CytRx has an agreement with Orphazyme that can yield potent...

Highlights Orphazyme’s Establishment of U.S. Headquarters in Chicago and Recruitment of More Than 30 U.S. Employees Comments That Orphazyme’s Investments in the U.S. are Intended to Support Regulatory Efforts and the Prospective Commercialization of Arimocl...

CytRx (CYTR): Q3 GAAP EPS of -$0.08.Cash and cash equivalents of $12.06M.10QPress Release For further details see: CytRx reports Q3 results

CytRx Corporation (OTCQB: CYTR) (“CytRx” or the “Company”), a specialized biopharmaceutical company focused on research and development for the oncology and neurodegenerative disease categories, today commented on its results for the third quarter ended Septe...